000			nab a22 7a 4500
999			_c17512 _d17512
003			PC17512
005			20230609132401.0
008			230609b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92950 _aAndradas, Clara _eInstituto de Investigación imas12
100			_92952 _aBlasco Benito, Sandra _eInstituto de Investigación imas12
100			_92951 _aPérez Gómez, Eduardo _eInstituto de Investigación imas12
100			_92953 _aSánchez, Cristina _eInstituto de Investigación imas12
245	0	0	_aActivation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. _h[artículo]
260			_bOncotarget, _c2016
300			_a7(30):47565-75.
500			_aFormato Vancouver: Andradas C, Blasco Benito S, Castillo Lluva S, Dillenburg Pilla P, Diez Alarcia R, Juanes García A et al. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget. 2016 Jul 26;7(30):47565-47575.
501			_aPMID: 27340777 PMC5216961
504			_aContiene 45 referencias
520			_aThe orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.
710			_9625 _aInstituto de Investigación imas12
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216961/pdf/oncotarget-07-47565.pdf _yAcceso libre
942			_2ddc _cART _n0